Repros Therapeutics Inc. (RPRX) Stock Research, Analysis & News

Quick Analysis on Repros Therapeutics Inc. (RPRX) Stock as of April 24, 2017

Previous Closing Price $1.01 is below its 50 day moving average $1.16
Previous Closing Price $1.01 is below its 200 day moving average $1.45
The Price/Earnings To Growth ratio (PEG) is less than 1
The Stock pays no dividend
The closing price $1.01 is more than 419.80% away from its one year target price of $5.25
Current Short Ratio 6.43 is great than 1
Next year EPS Estimate of $-0.73 is lower than curreny year EPS Estimate $-0.61
Earning per Share $-0.70 is negative. Repros Therapeutics Inc. is lossing money.
EBITDA $-17.32M is negative
It is a very small cap stock with market cap of $26.41M
(See more information about Repros Therapeutics Inc. (RPRX) Stock below)

Repros Therapeutics Inc. (RPRX) Stock Profile Summary

Repros Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. The companys primary product candidate includes Androxal that completed Phase IIb proof-of-concept trial in men being treated for low testosterone levels who want to improve or maintain their fertility and/or sperm number and function; and is in the Phase IIa clinical trial for the treatment of hypogonadal men with type 2 diabetes. It also offers phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006. Repros Therapeutics, Inc. was founded in 1987 and is based in The Woodlands, Texas.

Repros Therapeutics Inc. (RPRX) Stock Key Statistics Research and Analysis as of April 24, 2017

Stock ExchangeNCM
Market Capitalization$26.41M
Trade Volume (Average Trading Volume)404,936 (135,810)
Price/Book4.28
Earning/Share$-0.70
Current Year EPS Estimate$-0.61
Next Year EPS Estimate$-0.73
Previous Closing Price$1.01
50 Day Price Moving Average$1.16
200 Day Price Moving Average$1.45
1 yr Target Price$5.25
PEG Ratio-0.05
Short Ratio6.43
EBITDA$-17.32M

Repros Therapeutics Inc. (RPRX) Stock Competitor Research and Analysis

Abbott Laboratories (ABT)Auxilium Pharmaceuticals Inc. (AUXL)
Watson Pharmaceuticals Inc. (WPI)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)

Stock Research on Repros Therapeutics Inc. (RPRX)

Latest Market News on Repros Therapeutics Inc. (RPRX)


Click here to find the latest news on Repros Therapeutics Inc. (RPRX)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Abbott Laboratories (ABT)
Auxilium Pharmaceuticals Inc. (AUXL)
Watson Pharmaceuticals Inc. (WPI)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)